Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(1-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]cyclopropyl)carbamic acid
-
-
(1-[[(2S)-2-[[2-(2-amino-2-oxoethyl)-2-[[(2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl]hydrazinyl]carbonyl]pyrrolidin-1-yl]carbonyl]cyclopropyl)carbamic acid
-
-
(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidine-1-carboxylic acid
-
-
(2S)-2-[[2-(2-amino-2-oxoethyl)-2-[[(2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl]hydrazinyl]carbonyl]pyrrolidine-1-carboxylic acid
-
-
(2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2-[[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl](methanesulfonyl)amino]butanamide
-
(3-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]phenyl)carbamic acid
-
-
(3S)-3-[(1-acetyl-L-prolyl)amino]-5-[(2,6-dimethylbenzoyl)oxy]-4-oxopentanoic acid
-
starting structure for development of activity-based probes for in vivo imaging
(4-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]benzyl)carbamic acid
-
-
2,2-dimethyl-propionic acid 3-benzyloxycarbonylamino-4-carbamoyl-2-oxo-butyl ester
-
weak inhibition
2,6-dimethyl-benzoic acid 3-benzyloxycarbonylamino-4-carbamoyl-2-oxo-butyl ester
-
enters cells and causes complete, irreversible inhibition of the enzyme, inhibition of autocatalytic processing in vivo
2-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]piperidine-1-carboxylic acid
-
-
3-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]-3,4-dihydroisoquinoline-2(1H)-carboxylic acid
-
-
4-(2-aminoethyl) benzenesulfonyl fluoride
AEBSF, 45.8% inhibition at 5 mM
4-chloromercuribenzoate
-
-
4-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]-1,3-thiazolidine-3-carboxylic acid
-
-
Ac-Tyr-Val-Ala-Asp-chloromethylketone
the rate of inhibition by Asp-CMK is approximately 3times more rapid at pH 4.0 than at pH 5.5
acetyl-Glu-Ser-Glu-Asn-aldehyde
Acetyl-Tyr-Val-Ala-Asp-aldehyde
Ala-Ala-Asn-chloromethylketone
the rate of inhibition by Asn-CMK is approximately 1.3times more rapid at pH 5.5 than at pH 4.0
alpha-2-Macroglobulin
proteinase inhibitor, may be a candidate for the binding of legumain as it is an agent for the removal of endopeptidases from extracellular fluids
-
antipain
papain-like cysteine proteinase inhibitor, 28.77% inhibition at 0.1 mM concentration relative to control
asparaginyl endopeptidase inhibitor
-
i.e. AEPi or cysteine protease inhibitor
-
benzoic acid 3-benzyloxycarbonylamino-4-carbamoyl-2-oxo-butyl ester
-
-
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-benzyloxymethylketone
-
moderate inhibition
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-bromoacetate
-
-
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-bromomethylketone
-
strong specific and irreversible inhibition
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-chloroacetate
-
-
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-chloromethylketone
Benzyloxycarbonyl-Phe-Ala-CHN2
-
-
Boc-azaAsn-CH=CH-COOEt
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
Boc-Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
carbobenzyloxy-Ala-Ala-(aza-Asn)-epoxycarboxylate ethyl ester
caspase 1 inhibitor V
-
-
-
Cbz-Ala-Ala-azaAsn-CH=CH-COOEt
Cbz-Ala-Ile-azaAsn-CH=CH-COOEt
CBZ-Ala-Phe-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
CBZ-Ala-Phe-azaAsn-CH=CH-CONHCH2-furyl
-
-
Cbz-Ala-Val-azaAsn-CH=CH-CO-tetrahydroquinoline
Cbz-Ala-Val-azaAsn-CH=CH-CONHCH2-1-naphthyl
Cbz-Ala-Val-azaAsn-CH=CH-COOEt
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroquinoline
cystatin 3
strong inhibition
-
cystatin E
high affinity inhibitor of legumain
-
diisopropyl fluorophosphate
E-64
papain-like cysteine proteinase inhibitor, 7.51% inhibition at 0.3 mM concentration relative to control
egg white cystatin
concentration of 2 microM, 45.13% inhibition of recombinant protein activity
-
ethyl (2E)-4-[1-(2-amino-2-oxoethyl)-2-[[(2S)-1-(2-oxopropanoyl)pyrrolidin-2-yl]carbonyl]hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2E)-2-(acetylamino)but-2-enoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2R)-2-(acetylamino)-3-(4-hydroxy-3-nitrophenyl)propanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2R)-2-(acetylamino)butanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2R)-2-(acetylamino)pent-4-ynoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[2-(acetylamino)-2-methylpropanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[2-(acetylamino)-3-methylbut-2-enoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[3-(acetylamino)benzoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[4-(acetylamino)benzoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[(2R)-1-acetylpiperidin-2-yl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[(3S)-2-acetyl-1,2,3,4-tetrahydroisoquinolin-3-yl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[(4S)-3-acetyl-1,3-thiazolidin-4-yl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[1-(acetylamino)cyclopropyl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2S,3S)-3-[[1-(2-amino-2-oxoethyl)-2-[([2S)-1-(2-oxopropanoyl)pyrrolidin-2-yl]carbonyl]hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
ethyl (2S,3S)-3-[[2-([(2S)-1-[(2R)-2-(acetylamino)butanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
ethyl (2S,3S)-3-[[2-([(2S)-1-[(2R)-2-(acetylamino)pent-4-ynoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
ethyl (2S,3S)-3-[[2-[[(2S)-1-acetylpyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
starting structure for development of activity-based probes for in vivo imaging
ethyl (2S,3S)-3-[[2-[[(2S)-1-[[1-(acetylamino)cyclopropyl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
FaCPI-1
-
strawberry cystatin, phytocystatin of Fragaria sp.
-
High molecular weight kininogen
-
-
-
High-molecular mass kininogen
kinin-free, F1.2-free
-
human cystatin C mutant L9G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin C mutant N39K
-
reduced inhibitory effect compared to the wild-type cystatin C
-
human cystatin C mutant R8G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin C mutant V10G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin C mutant W106G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin E/M
-
type 2 cystatin
-
human cystatin F
-
type 2 cystatin
-
HvCPI-4
-
cystatin HvCPI-4 of Hordeum vulgare
-
HvCPI-4-deltaT143-Cterm
-
C-terminal extended part of cystatin HvCPI-4
-
HvCPI-4-deltaT151-Cterm
-
C-terminal extended part of cystatin HvCPI-4
-
HvCPI-4-Q86P
-
cystatin HvCPI-4 of Hordeum vulgare, mutant Q86P
-
iodoacetic acid
0.1 mM, 82.4% remaining activity
L-3-carboxy-2,3-trans-epoxypropionyl-leucyl-amido(4-guanidino)butane
low molecular mass kininogen
-
-
Mu-Ala-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
Mu-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Mu-Ala-Ala-azaAsn-CH=CH-CONHCH2CH2CH2Ph
-
-
Mu-Ala-Ala-azaAsn-CH=CH-COOEt
Mu-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
Mu-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
Mu-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone
0.1 mM, 0.23% remaining activity
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(2',4'-dichloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(2'-chloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(2,4-dichlorobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(3',4'-dichloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(3',4'-difluoro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(3'-fluoro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-chloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-cyano[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-ethyl[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-methoxy[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-methyl[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-tert-butyl[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4-bromobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4-chlorobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4-fluorobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-([1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4'-(propan-2-yl)[1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4'-[(propan-2-yl)oxy][1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4-(2H-1,3-benzodioxol-5-yl)benzene-1-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4-(trifluoromethyl)benzene-1-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(1-methyl-1H-indazol-5-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(1-methyl-1H-indazol-7-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(2-methyl-2H-indazol-5-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(2-methyl-2H-indazol-7-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(4-methylpyridin-3-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(5-methylpyridin-3-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-[4-(trifluoromethyl)pyridin-3-yl]benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-[5-(trifluoromethyl)pyridin-3-yl]benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(2',3'-difluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(2',4'-dichloro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(2',4'-difluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(3',5'-difluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(3'-fluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-butyl[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-chloro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-fluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-tert-butyl[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-([1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(1,3-benzothiazol-5-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(4-chloropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(4-fluoropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(4-tert-butylpyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(5-chloropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(5-fluoropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(ethanesulfonyl)-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-propoxy[1,1'-biphenyl]-4-yl)methyl]-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-propoxy[1,1'-biphenyl]-4-yl)methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(2-methylpropane-1-sulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(ethanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-norvalinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(propane-1-sulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3',5'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-chloro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-ethoxy[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(2-methylpropane-1-sulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-norvalinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E)-4-oxo-4-phenylbut-2-enoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E,4E)-hexa-2,4-dienoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
N-[(benzyloxy)carbonyl]-L-alanyl-N-[(1S,3E)-1-(2-amino-2-oxoethyl)-5-[methyl(naphthalen-1-yl)amino]-2,5-dioxopent-3-en-1-yl]-L-alaninamide
i.e. aza-peptide Michael acceptor Aza-Asn-11a, inhibition of trans-processing and activation of the zymogen form of Schistosoma mansoni cathepsin B1 by prior incubation with the legumain-specific inhibitor Aza-Asn-11a, reaction in CPS buffer, pH 5.5 for 30 min
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1,3-dihydroisoindol-2-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1-piperidylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2,3-dihydroindol-1-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2-furyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-1H-quinolin-2-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3-pyridyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-fluorobenzyl)carbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methyl-1-naphthylmethylcarbamoyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenethylcarbamoyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenylcarbamoyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylmethylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-bis-(2-furylmethyl)carbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibenzylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibutylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-diethylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenethylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylbenzylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-3-(N-methyl-N-(1-(N-methyl-N-phenethylcarbamoyl)phenylethyl)carbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl(4-fluorobenzyl)carbamoylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-1-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-2-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyloxycarbonylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-biotinylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
p-chloromercuribenzene sulfonic acid
-
-
p-chloromercuribenzene-sulfonic acid
-
p-chloromercuribenzoate
-
-
pepstatin
concentration of 500 microM, 7.8% inhibition of recombinant protein activity
phenylmethanesulfonyl fluoride
phenylmethylsulfonyl fluoride
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)-CH2-1-naphthyl
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
Pip-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Pip-Ala-Ala-azaAsn-CH=CH-CONHCH2CH2Ph
Pip-Ala-Ala-azaAsn-CH=CH-COOEt
Pip-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
Pip-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
Pip-Ala-Ala-azaAsn-EP(S,S)-COOEt
Pip-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
Piz-Ala-Ala-azaAsn-CH=CH-COOEt
Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
PMSF
serine peptidase inhibitor, 13.84% inhibition at 5 mM concentration relative to control
rat alpha1-macroglobulin
-
-
-
trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane
trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane
E-64, concentration of 500 microM, 8.88% inhibition of recombinant protein activity
Z-Phe-Ala-CHN2
i.e. benzyloxycarbonyl-phenylalanyl-alanyl-diazomethane, 40.8% inhibition at 0.01 mM
[(2S)-1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-3-[4-hydroxy-3-[hydroxy(oxo)ammonio]phenyl]-1-oxopropan-2-yl]carbamate
-
-
[(2Z)-1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-1-oxobut-2-en-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-1-oxopent-4-yn-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-2-methyl-1-oxopropan-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobut-2-en-2-yl]carbamic acid
-
-
[1-[(2S)-2-[[2-(2-amino-2-oxoethyl)-2-[[(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl]hydrazinyl]carbonyl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamic acid
-
-
1,10-phenanthroline
concentration of 1 mM, 10 min before addition of substrate, 40% inhibition; concentration of 1mM, 10 min before addition of substrate, 40% inhibition observed
1,10-phenanthroline
27.5% inhibition at 5 mM
acetyl-Glu-Ser-Glu-Asn-aldehyde
-
hydrolysis of the the Asn-containing substrate inhibited in a concentration-dependent manner
acetyl-Glu-Ser-Glu-Asn-aldehyde
-
hydrolysis of the the Asn-containing substrate inhibited in a concentration-dependent manner
acetyl-Glu-Ser-Glu-Asn-aldehyde
-
hydrolysis of the the Asn-containing substrate inhibited in a concentration-dependent manner
Acetyl-Tyr-Val-Ala-Asp-aldehyde
-
hydrolysis of the the Asn-containing substrate inhibited in a concentration-dependent manner, reduced amounts of cyclic cyclotide produced in transiently transformed tobacco leaves determined
Acetyl-Tyr-Val-Ala-Asp-aldehyde
-
hydrolysis of the the Asn-containing substrate inhibited in a concentration-dependent manner
Acetyl-Tyr-Val-Ala-Asp-aldehyde
-
hydrolysis of the the Asn-containing substrate inhibited in a concentration-dependent manner
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-chloromethylketone
Z-Ala-Ala-AzaAsn-CMK, 1 microM, 10 min before addition of substrate, 100% inhibition; Z-Ala-Ala-AzaAsn-CMK, 1 microM, 10 min before addition of substrate, 100% inhibition observed
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-chloromethylketone
-
strong specific and irreversible inhibition
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Boc-Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
Boc-Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
carbobenzyloxy-Ala-Ala-(aza-Asn)-epoxycarboxylate ethyl ester
-
carbobenzyloxy-Ala-Ala-(aza-Asn)-epoxycarboxylate ethyl ester
-
Cbz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Cbz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Cbz-Ala-Ile-azaAsn-CH=CH-COOEt
-
-
Cbz-Ala-Ile-azaAsn-CH=CH-COOEt
-
-
Cbz-Ala-Val-azaAsn-CH=CH-CO-tetrahydroquinoline
-
-
Cbz-Ala-Val-azaAsn-CH=CH-CO-tetrahydroquinoline
-
-
Cbz-Ala-Val-azaAsn-CH=CH-CONHCH2-1-naphthyl
-
-
Cbz-Ala-Val-azaAsn-CH=CH-CONHCH2-1-naphthyl
-
-
Cbz-Ala-Val-azaAsn-CH=CH-COOEt
-
-
Cbz-Ala-Val-azaAsn-CH=CH-COOEt
-
-
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
-
-
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
-
-
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroquinoline
-
-
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroquinoline
-
-
Cu2+
strong inhibition
cystatin
-
from egg-white
-
cystatin
0.1 mM, 90.5% remaining activity
-
cystatin
from egg white, 62.3% inhibition at 0.003 mM concentration relative to control
-
cystatin
-
from chicken egg white
-
cystatin C
-
-
cystatin C
-
endogenous inhibitor
-
cystatin E/M
-
-
-
cystatin E/M
-
cystatin E/M controls both intra- and extracellular legumain activity
-
cystatin M
high affinity inhibitor of legumain
-
cystatin M
-
specific endogenous inhibitor of lysosomal cysteine proteases, diverse tissue distribution, target specificity, and biological function, overview, high expression level in MDA-686Ln cells, silencing of cystatin M by siRNA leads to increased enzyme activity in MDA-686Ln cells
-
diisopropyl fluorophosphate
-
-
diisopropyl fluorophosphate
-
not
E64
17.1% inhibition at 0.001 mM
E64
slight inhibition at 1 mM
Hg2+
strong inhibition
Human cystatin C
-
-
-
Human cystatin C
-
competitive inhibition
-
iodoacetamide
-
-
iodoacetamide
concentration of 5 mM,10 min before addition of substrate, 100% inhibition; concentration of 5 mM, 10 min before addition of substrate, 100% inhibition determined
iodoacetamide
concentration of 3 mM, 100% inhibition of recombinant protein activity, BSA cleavage inhibited by 5 mM iodoacetamide
iodoacetamide
100% inhibition at 3 mM concentration relative to control
iodoacetamide
complete inhibition at 5 mM inhibitor concentration
iodoacetamide
11.6% remaining activity
iodoacetamide
irreversible millimolar inhibitor
iodoacetate
-
-
iodoacetate
55.8 remaining activity
L-3-carboxy-2,3-trans-epoxypropionyl-leucyl-amido(4-guanidino)butane
-
-
L-3-carboxy-2,3-trans-epoxypropionyl-leucyl-amido(4-guanidino)butane
-
i.e. E-64, not
leupeptin
-
-
leupeptin
concentration of 300 microM, 16.07% inhibition of recombinant protein activity
leupeptin
papain-like cysteine proteinase inhibitor, 3.9% inhibition at 0.3 mM concentration relative to control
leupeptin
47.3% inhibition at 1 mM
leupeptin
slight inhibition at 1 mM
Mu-Ala-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
Mu-Ala-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
Mu-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Mu-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Mu-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Mu-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Mu-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
Mu-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
Mu-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
-
-
Mu-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
-
-
Mu-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
Mu-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
N-ethylmaleimide
-
N-ethylmaleimide
concentration of 3 mM, 95.74% inhibition of recombinant protein activity
N-ethylmaleimide
100% inhibition at 3 mM concentration relative to control
N-ethylmaleimide
complete inhibition at 2 mM
N-ethylmaleimide
16.6% remaining activity
N-Phenylmaleimide
-
-
N-Phenylmaleimide
-
strong inhibition
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E)-4-oxo-4-phenylbut-2-enoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
-
-
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E)-4-oxo-4-phenylbut-2-enoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
-
-
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E)-4-oxo-4-phenylbut-2-enoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
-
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E,4E)-hexa-2,4-dienoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
-
-
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E,4E)-hexa-2,4-dienoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
-
-
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E,4E)-hexa-2,4-dienoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1,3-dihydroisoindol-2-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1,3-dihydroisoindol-2-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1,3-dihydroisoindol-2-ylcarbonyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1-piperidylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1-piperidylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1-piperidylcarbonyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2,3-dihydroindol-1-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2,3-dihydroindol-1-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2,3-dihydroindol-1-ylcarbonyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2-furyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2-furyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2-furyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-1H-quinolin-2-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-1H-quinolin-2-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-1H-quinolin-2-ylcarbonyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-ylcarbonyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3-pyridyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3-pyridyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3-pyridyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-fluorobenzyl)carbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-fluorobenzyl)carbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-fluorobenzyl)carbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methyl-1-naphthylmethylcarbamoyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methyl-1-naphthylmethylcarbamoyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methyl-1-naphthylmethylcarbamoyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenethylcarbamoyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenethylcarbamoyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenethylcarbamoyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenylcarbamoyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenylcarbamoyl)propenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenylcarbamoyl)propenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylmethylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylmethylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylmethylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-bis-(2-furylmethyl)carbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-bis-(2-furylmethyl)carbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-bis-(2-furylmethyl)carbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibenzylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibenzylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibenzylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibutylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibutylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibutylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-diethylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-diethylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-diethylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenethylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenethylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenethylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylbenzylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylbenzylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylbenzylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylcarbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylcarbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-3-(N-methyl-N-(1-(N-methyl-N-phenethylcarbamoyl)phenylethyl)carbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-3-(N-methyl-N-(1-(N-methyl-N-phenethylcarbamoyl)phenylethyl)carbamoylpropenoyl)hydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-3-(N-methyl-N-(1-(N-methyl-N-phenethylcarbamoyl)phenylethyl)carbamoylpropenoyl)hydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl(4-fluorobenzyl)carbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl(4-fluorobenzyl)carbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl(4-fluorobenzyl)carbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-1-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-1-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-1-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-2-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-2-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-2-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyloxycarbonylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyloxycarbonylpropenoyl)-N1-carbamoylmethylhydrazine
-
-
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyloxycarbonylpropenoyl)-N1-carbamoylmethylhydrazine
-
N2-(N-biotinylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
-
-
N2-(N-biotinylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
-
-
N2-(N-biotinylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
-
NEM
-
-
ovocystatin
-
weak inhibition, from egg-white
-
ovocystatin
-
from egg-white
-
ovocystatin
-
from chicken egg white
-
PCMB
-
-
pepstatin A
0.01 mM, 86.9% remaining activity
pepstatin A
aspartic peptidase inhibitor has minimal effects on the enzyme activity, 12.22% inhibition at 0.3 mM concentration relative to control
pepstatin A
8.4% inhibition at 0.1 mM
pepstatin A
-
no effect on ability to cleave the Asn-containing substrate
pepstatin A
-
no effect on ability to cleave the Asn-containing substrate
pepstatin A
-
no effect on ability to cleave the Asn-containing substrate
phenylmethanesulfonyl fluoride
PMSF, concentration of 2 mM, 10 min before addition of substrate, 66% inhibition; PMSF, concentration of 2 mM, 10 min before addition of substrate, 66% inhibition shown
phenylmethanesulfonyl fluoride
PMSF, concentration of 5 mM, 19% inhibition of recombinant protein activity
phenylmethylsulfonyl fluoride
-
no effect on ability to cleave the Asn-containing substrate
phenylmethylsulfonyl fluoride
-
no effect on ability to cleave the Asn-containing substrate
phenylmethylsulfonyl fluoride
-
no effect on ability to cleave the Asn-containing substrate
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)-CH2-1-naphthyl
-
-
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)-CH2-1-naphthyl
-
-
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
-
-
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
-
-
Pip-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Pip-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Pip-Ala-Ala-azaAsn-CH=CH-CONHCH2CH2Ph
-
-
Pip-Ala-Ala-azaAsn-CH=CH-CONHCH2CH2Ph
-
-
Pip-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Pip-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Pip-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
Pip-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
Pip-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
-
-
Pip-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
-
-
Pip-Ala-Ala-azaAsn-EP(S,S)-COOEt
-
-
Pip-Ala-Ala-azaAsn-EP(S,S)-COOEt
-
-
Pip-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
Pip-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
-
-
Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
-
-
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
-
-
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
-
-
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
-
-
Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
-
-
Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
-
-
Piz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Piz-Ala-Ala-azaAsn-CH=CH-COOEt
-
-
Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
-
-
trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane
-
i.e. E-64, no effect on ability to cleave the Asn-containing substrate
trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane
-
i.e. E-64, no effect on ability to cleave the Asn-containing substrate
trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane
-
i.e. E-64, no effect on abilityto cleave the Asn-containing substrate
additional information
no inhibition by E-64, leupeptin, and elastatinal
-
additional information
-
no inhibition by E-64, leupeptin, and elastatinal
-
additional information
the enzyme is not inhibited by the broad spectrum cysteine protease inhibitors E-64, PMSF nor by the aspartate protease inhibitor pepstatin A
-
additional information
-
no inhibition by E64
-
additional information
no inhibition by the general cysteine protease inhibitor E-64
-
additional information
-
no inhibition by the general cysteine protease inhibitor E-64
-
additional information
no significant inhibition by trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) in a concentration of 10 microM, leupeptin in a concentration of 10 microM or pepstatin in a concentration of 5 microM; no significant inhibition observed by using trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) in a concentration of 10 microM, leupeptin in a concentration of 10 microM or pepstatin in a concentration of 5 microM
-
additional information
no significant inhibition by trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) in a concentration of 10 microM, leupeptin in a concentration of 10 microM or pepstatin in a concentration of 5 microM; no significant inhibition observed by using trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) in a concentration of 10 microM, leupeptin in a concentration of 10 microM or pepstatin in a concentration of 5 microM
-
additional information
-
no significant inhibition by trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) in a concentration of 10 microM, leupeptin in a concentration of 10 microM or pepstatin in a concentration of 5 microM; no significant inhibition observed by using trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane (E-64) in a concentration of 10 microM, leupeptin in a concentration of 10 microM or pepstatin in a concentration of 5 microM
-
additional information
-
alpha2-macroglobulin; leupeptin; not: EDTA; pepstatin
-
additional information
-
no inhibition by E-64 and leupeptin
-
additional information
-
the enzyme expression is reduced by lipopolysaccharide priming and in endotoxin-tolerant monocytes
-
additional information
inhibitory activity of the phytocystatins HvCPI-4 of Hordeum vulgare and FaCPI-1 of Fragaria sp. measured by the inhibition of legumain proteinase activity, ability of HvCPI-4 and FaCPI-1 to inhibit human legumain in vitro demonstrated
-
additional information
-
inhibitory activity of the phytocystatins HvCPI-4 of Hordeum vulgare and FaCPI-1 of Fragaria sp. measured by the inhibition of legumain proteinase activity, ability of HvCPI-4 and FaCPI-1 to inhibit human legumain in vitro demonstrated
-
additional information
inhibitor specificity profiles of cathepsin B and legumain regarded and used for analysis of the suitability of fluorescent activity-based probes
-
additional information
-
inhibitor specificity profiles of cathepsin B and legumain regarded and used for analysis of the suitability of fluorescent activity-based probes
-
additional information
the enzyme is not inhibited by the broad spectrum cysteine protease inhibitors E-64, PMSF nor by the aspartate protease inhibitor pepstatin A
-
additional information
-
the enzyme is not inhibited by the broad spectrum cysteine protease inhibitors E-64, PMSF nor by the aspartate protease inhibitor pepstatin A
-
additional information
-
inhibitory activity measured by the inhibition of legumain proteinase activity, phytocystatins that are able to inhibit human legumain also inhibit the barley legumain proteinase activities in developing roots, endogenous barley legumain activities inhibited by iodoacetamide, no inhibition by the non-legumain inhibitors leupeptin and E64 observed; inhibitory effects against endogenous legumain activity in barley protein extracts tested, inhibitory activity measured by the inhibition of legumain-like proteinase activity, phytocystatins able to inhibit human legumain also inhibit the barley legumain proteinase activities in developing endosperms, endogenous barley legumain activities inhibited by iodoacetamide, no inhibition by the non-legumain inhibitors leupeptin and E64 observed
-
additional information
-
the enzyme is not inhibited by the broad spectrum cysteine protease inhibitors E-64, PMSF nor by the aspartate protease inhibitor pepstatin A
-
additional information
-
no inhibition by leupeptin
-
additional information
-
not: EDTA; phenylmethylsulfonyl fluoride
-
additional information
no inhibition with EDTA, PMSF, pepstatin A, leupeptin, and E-64
-
additional information
-
no inhibition with EDTA, PMSF, pepstatin A, leupeptin, and E-64
-
additional information
E-64 has no effect on enzyme activity
-
additional information
no inhibition by Z-Phe-Ala-CHN2 and 1,10-phenanthroline
-
additional information
no inhibition by Z-Phe-Ala-CHN2 and 1,10-phenanthroline
-
additional information
the enzyme is not inhibited by the broad spectrum cysteine protease inhibitors E-64, PMSF nor by the aspartate protease inhibitor pepstatin A
-
additional information
-
glycosylation of asparaginyl residues totally prevents cleavage by the enzyme, no binding to human alpha2-macroglobulin
-
additional information
-
no inhibition by PMSF, EDTA and 1,10-phenanthroline
-
additional information
-
construction and irreversible specific inhibition of the enzyme by several derivatives of Michael acceptor inhibitors based on the backbone benzyloxycarbonal-L-Ala-L-Ala-L-Asn, overview
-
additional information
-
no inhibition by E-64 and EDTA
-
additional information
-
no inhibition by E-64, i.e. trans-epoxysuccinyl-L-leucylamido-(4-guanidino)-butane, no inhibition by PMSF, pepstatin and 1,10-phenanthroline
-
additional information
-
inhibition mechanism by human cystatins, enzyme inhibitor complex formation analysis, no inhibition by human type 1 cystatins A and B, type 2 cystatin D, and type 3 low MW kininogen
-
additional information
-
no inhibition by E64 and leupeptin
-
additional information
-
the enzyme is not inhibited by the broad spectrum cysteine protease inhibitors E-64, PMSF nor by the aspartate protease inhibitor pepstatin A
-
additional information
-
-
-
additional information
-
not: EDTA; N-tosyl-L-lysine chloromethyl ketone; phenylmethylsulfonyl fluoride
-